Abstract:Like other autoimmune diseases, rheumatoid arthritis (RA) develops in distinct stages, with each phase of disease linked to immune cell dysfunction. HLA class II genes confer the strongest genetic risk to develop RA. They encode for molecules essential in the activation and differentiation of T cells, placing T cells upstream in the immunopathology. In Phase 1 of the RA disease process, T cells lose a fundamental function, their ability to be self-tolerant, and provide help for autoantibody-producing B cells. Phase 2 begins many years later, when mis-differentiated T cells gain tissue-invasive effector functions, enter the joint, promote non-resolving inflammation, and give rise to clinically relevant arthritis. In Phase 3 of the RA disease process, abnormal innate immune functions are added to adaptive autoimmunity, converting synovial inflammation into a tissue-destructive process that erodes cartilage and bone. Emerging data have implicated metabolic mis-regulation as a fundamental pathogenic pathway in all phases of RA. Early in their life cycle, RA T cells fail to repair mitochondrial DNA, resulting in a malfunctioning metabolic machinery. Mitochondrial insufficiency is aggravated by the mis-trafficking of the energy sensor AMPK away from the lysosomal surface. The metabolic signature of RA T cells is characterized by the shunting of glucose toward the pentose phosphate pathway and toward biosynthetic activity. During the intermediate and terminal phase of RA-imposed tissue inflammation, tissue-residing macrophages, T cells, B cells and stromal cells are chronically activated and under high metabolic stress, creating a microenvironment poor in oxygen and glucose, but rich in metabolic intermediates, such as lactate. By sensing tissue lactate, synovial T cells lose their mobility and are trapped in the tissue niche. The linkage of defective DNA repair, misbalanced metabolic pathways, autoimmunity, and tissue inflammation in RA encourages metabolic interference as a novel treatment strategy during both the early stages of tolerance breakdown and the late stages of tissue inflammation. Defining and targeting metabolic abnormalities provides a new paradigm to treat, or even prevent, the cellular defects underlying autoimmune disease.

Cellular metabolic adaptations in rheumatoid arthritis and their therapeutic implications

Review: Synovial Cell Metabolism and Chronic Inflammation in Rheumatoid Arthritis

The interplay between inflammation and metabolism in rheumatoid arthritis

Metabolic Control of Autoimmunity and Tissue Inflammation in Rheumatoid Arthritis

Metabolic Signatures of T-cells and Macrophages in Rheumatoid Arthritis.

Metabolic reprogramming as a key regulator in the pathogenesis of rheumatoid arthritis

T-cell metabolism in rheumatoid arthritis: focus on mitochondrial and lysosomal dysfunction

Targeting dysregulated intracellular immunometabolism within synovial microenvironment in rheumatoid arthritis with natural products

CD31 orchestrates metabolic regulation in autophagy pathways of rheumatoid arthritis

Mitochondrial Dysfunction and Oxidative Stress in Rheumatoid Arthritis

Immuno-metabolic reprogramming of T cell: a new frontier for pharmacotherapy of Rheumatoid arthritis

Metabolic changes in fibroblast-like synoviocytes in rheumatoid arthritis: state of the art review

Cellular deconstruction of inflamed synovium defines diverse inflammatory phenotypes in rheumatoid arthritis

Critical Role of Synovial Tissue-Resident Macrophage and Fibroblast Subsets in the Persistence of Joint Inflammation

Defective glucose and lipid metabolism in rheumatoid arthritis is determined by chronic inflammation in metabolic tissues

Rheumatoid arthritis macrophages are primed for inflammation and display bioenergetic and functional alterations

Hypoxia: how does the monocyte-macrophage system respond to changes in oxygen availability?

Macrophage polarization in rheumatoid arthritis: signaling pathways, metabolic reprogramming, and crosstalk with synovial fibroblasts

Target effector role of vascular endothelium in the inflammatory response: insights from the clinical trial of anti-TNF alpha antibody in rheumatoid arthritis.

Distinct stromal and immune cell interactions shape the pathogenesis of rheumatoid and psoriatic arthritis

Regulation of Sirt1 on energy metabolism and immune response in rheumatoid arthritis